{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:06:18Z","timestamp":1790658378669,"version":"4.1.0"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T00:00:00Z","timestamp":1594598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Nanotechnol."],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1038\/s41565-020-0732-3","type":"journal-article","created":{"date-parts":[[2020,7,13]],"date-time":"2020-07-13T10:04:30Z","timestamp":1594634670000},"page":"630-645","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":273,"title":["Immune-mediated approaches against COVID-19"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4006-5840","authenticated-orcid":false,"given":"Helena F.","family":"Florindo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Kleiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniella","family":"Vaskovich-Koubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita C.","family":"Ac\u00farcio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Carreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eilam","family":"Yeini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galia","family":"Tiram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Liubomirski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7360-7837","authenticated-orcid":false,"given":"Ronit","family":"Satchi-Fainaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,13]]},"reference":[{"key":"732_CR1","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.3201\/eid1107.050219","volume":"11","author":"S Jiang","year":"2005","unstructured":"Jiang, S., He, Y. & Liu, S. SARS vaccine development. Emerg. Infect. Dis. 11, 1016\u20131020 (2005).","journal-title":"Emerg. Infect. Dis."},{"key":"732_CR2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1086\/422040","volume":"190","author":"DT Leung","year":"2004","unstructured":"Leung, D. T. et al. Antibody response of patients with severe acute respiratory syndrome (SARS) targets the viral nucleocapsid. J. Infect. Dis. 190, 379\u2013386 (2004).","journal-title":"J. Infect. Dis."},{"key":"732_CR3","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1128\/JCM.43.8.3718-3726.2005","volume":"43","author":"Y He","year":"2005","unstructured":"He, Y., Zhou, Y., Siddiqui, P., Niu, J. & Jiang, S. Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. J. Clin. Microbiol. 43, 3718\u20133726 (2005).","journal-title":"J. Clin. Microbiol."},{"key":"732_CR4","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s12985-019-1182-0","volume":"16","author":"D Schoeman","year":"2019","unstructured":"Schoeman, D. & Fielding, B. C. Coronavirus envelope protein: current knowledge. Virol. J. 16, 69 (2019).","journal-title":"Virol. J."},{"key":"732_CR5","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.micinf.2020.01.003","volume":"22","author":"F Yu","year":"2020","unstructured":"Yu, F., Du, L., Ojcius, D. M., Pan, C. & Jiang, S. Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 22, 74\u201379 (2020).","journal-title":"Microbes Infect."},{"key":"732_CR6","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41579-018-0118-9","volume":"17","author":"J Cui","year":"2019","unstructured":"Cui, J., Li, F. & Shi, Z. L. Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181\u2013192 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"732_CR7","doi-asserted-by":"crossref","unstructured":"Baez-Santos, Y. M., St John, S. E. & Mesecar, A. D. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds. Antiviral Res. 115, 21\u201338 (2015).","DOI":"10.1016\/j.antiviral.2014.12.015"},{"key":"732_CR8","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1099\/0022-1317-81-4-853","volume":"81","author":"J Ziebuhr","year":"2000","unstructured":"Ziebuhr, J., Snijder, E. J. & Gorbalenya, A. E. Virus-encoded proteinases and proteolytic processing in the Nidovirales. J. Gen. Virol. 81, 853\u2013879 (2000).","journal-title":"J. Gen. Virol."},{"key":"732_CR9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.7326\/M20-0504","volume":"172","author":"SA Lauer","year":"2020","unstructured":"Lauer, S. A. et al. The incubation period of coronavirus disease 2019 (covid-19) from publicly reported confirmed cases: Estimation and application. Ann. Intern. Med. 172, 577\u2013582 (2020).","journal-title":"Ann. Intern. Med."},{"key":"732_CR10","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1056\/NEJMoa2001316","volume":"382","author":"Q Li","year":"2020","unstructured":"Li, Q. et al. Early transmission dynamics in Wuhan, China, of bovel Coronavirus-infected pneumonia. N. Engl. J. Med. 382, 1199\u20131207 (2020).","journal-title":"N. Engl. J. Med."},{"key":"732_CR11","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1001\/jama.2020.2565","volume":"323","author":"Y Bai","year":"2020","unstructured":"Bai, Y. et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA 323, 1406\u20131407 (2020).","journal-title":"JAMA"},{"key":"732_CR12","unstructured":"Kluge, H. Older people are at highest risk from COVID-19, but all must act to prevent community spread. World Health Organization for Europe http:\/\/www.euro.who.int\/en\/health-topics\/health-emergencies\/coronavirus-covid-19\/statements\/statement-older-people-are-at-highest-risk-from-covid-19,-but-all-must-act-to-prevent-community-spread (2020)."},{"key":"732_CR13","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497\u2013506 (2020).","journal-title":"Lancet"},{"key":"732_CR14","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1021\/acschemneuro.0c00122","volume":"11","author":"AM Baig","year":"2020","unstructured":"Baig, A. M., Khaleeq, A., Ali, U. & Syeda, H. Evidence of the COVID-19 virus targeting the CNS: Tissue distribution, host-virus interaction, and proposed neurotropic mechanisms. ACS Chem. Neurosci. 11, 995\u2013998 (2020).","journal-title":"ACS Chem. Neurosci."},{"key":"732_CR15","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","volume":"8","author":"X Yang","year":"2020","unstructured":"Yang, X. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 8, 475\u2013481 (2020).","journal-title":"Lancet Respir. Med."},{"key":"732_CR16","doi-asserted-by":"crossref","unstructured":"Wadman, M. C.-F., J, Kaiser, J & Matacic, C. How does coronavirus kill? Clinicians trace a ferocious rampage through the body, from brain to toes. Science https:\/\/www.sciencemag.org\/news\/2020\/04\/how-does-coronavirus-kill-clinicians-trace-ferocious-rampage-through-body-brain-toes (2020).","DOI":"10.1126\/science.abc3208"},{"key":"732_CR17","first-page":"e200950","volume":"25","author":"S Shi","year":"2020","unstructured":"Shi, S. et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 25, e200950 (2020).","journal-title":"JAMA Cardiol."},{"key":"732_CR18","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1056\/NEJMc2009787","volume":"382","author":"TJ Oxley","year":"2020","unstructured":"Oxley, T. J. et al. Large-vessel stroke as a presenting feature of Covid-19 in the young. N. Engl. J. Med. 382, e60 (2020).","journal-title":"N. Engl. J. Med."},{"key":"732_CR19","unstructured":"Gilead announces approval of Veklury\u00ae (remdesivir) in Japan for patients with severe COVID-19. GILEAD https:\/\/www.gilead.com\/news-and-press\/press-room\/press-releases\/2020\/5\/gilead-announces-approval-of-veklury-remdesivir-in-japan-for-patients-with-severe-covid19 (2020)."},{"key":"732_CR20","unstructured":"Coronavirus (COVID-19) update: FDA issues emergency use authorization for potential COVID-19tTreatment. FDA https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment (2020)."},{"key":"732_CR21","unstructured":"Drugs@FDA: FDA-approved drugs. FDA https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm?event=overview.process&varApplNo=009768 (2020)."},{"key":"732_CR22","unstructured":"Recommendations for investigational COVID-19 convalescent plasma. FDA https:\/\/www.fda.gov\/vaccines-blood-biologics\/investigational-new-drug-ind-or-device-exemption-ide-process-cber\/investigational-covid-19-convalescent-plasma-emergency-inds (2020)."},{"key":"732_CR23","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"C Shen","year":"2020","unstructured":"Shen, C. et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA 323, 1582\u20131589 (2020).","journal-title":"JAMA"},{"key":"732_CR24","unstructured":"A study of LY3819253 (LY-CoV555) in participants hospitalized for COVID-19. NIH https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04411628?term=LY-CoV555&cond=COVID-19&draw=2&rank=1 (2020)."},{"key":"732_CR25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(20)30251-8","volume":"395","author":"R Lu","year":"2020","unstructured":"Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565\u2013574 (2020).","journal-title":"Lancet"},{"key":"732_CR26","doi-asserted-by":"crossref","first-page":"254","DOI":"10.3390\/v12030254","volume":"12","author":"SF Ahmed","year":"2020","unstructured":"Ahmed, S. F., Quadeer, A. A. & McKay, M. R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12, 254 (2020).","journal-title":"Viruses"},{"key":"732_CR27","doi-asserted-by":"crossref","first-page":"244","DOI":"10.3390\/v12020244","volume":"12","author":"J Xu","year":"2020","unstructured":"Xu, J. et al. Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses 12, 244 (2020).","journal-title":"Viruses"},{"key":"732_CR28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/1471-2180-3-20","volume":"3","author":"Y Kliger","year":"2003","unstructured":"Kliger, Y. & Levanon, E. Y. Cloaked similarity between HIV-1 and SARS-CoV suggests an anti-SARS strategy. BMC Microbiol. 3, 20 (2003).","journal-title":"BMC Microbiol."},{"key":"732_CR29","first-page":"e00399","volume":"64","author":"MA Martinez","year":"2020","unstructured":"Martinez, M. A. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob. Agents Chemother. 64, e00399\u201300320 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"732_CR30","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou, P. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270\u2013273 (2020).","journal-title":"Nature"},{"key":"732_CR31","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","volume":"197","author":"YM Arabi","year":"2018","unstructured":"Arabi, Y. M. et al. Corticosteroid therapy for critically ill patients with Middle East Respiratory Syndrome. Am. J. Respir. Crit. Care Med. 197, 757\u2013767 (2018).","journal-title":"J. Respir. Crit. Care Med."},{"key":"732_CR32","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1164\/rccm.201712-2371ED","volume":"197","author":"DS Hui","year":"2018","unstructured":"Hui, D. S. Systemic corticosteroid therapy may delay viral clearance in patients with Middle East Respiratory Syndrome coronavirus infection. Am. J. Respir. Crit. Care Med. 197, 700\u2013701 (2018).","journal-title":"J. Respir. Crit. Care Med."},{"key":"732_CR33","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S1473-3099(20)30196-1","volume":"20","author":"KK To","year":"2020","unstructured":"To, K. K. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 20, 565\u2013574 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"732_CR34","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1093\/rheumatology\/kez265","volume":"59","author":"R Fleischmann","year":"2020","unstructured":"Fleischmann, R. et al. Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years\u2019 follow-up. Rheumatology (Oxford) 59, 292\u2013302 (2020).","journal-title":"Rheumatology (Oxford)"},{"key":"732_CR35","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1089\/vim.2011.0099","volume":"25","author":"W Hu","year":"2012","unstructured":"Hu, W., Yen, Y. T., Singh, S., Kao, C. L. & Wu-Hsieh, B. A. SARS-CoV regulates immune function-related gene expression in human monocytic cells. Viral Immunol. 25, 277\u2013288 (2012).","journal-title":"Viral Immunol."},{"key":"732_CR36","first-page":"1","volume":"38","author":"E Prompetchara","year":"2020","unstructured":"Prompetchara, E., Ketloy, C. & Palaga, T. Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac. J. Allergy Immunol. 38, 1\u20139 (2020).","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"732_CR37","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejphar.2017.10.035","volume":"818","author":"MM Leiva-Juarez","year":"2018","unstructured":"Leiva-Juarez, M. M. et al. Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir. Eur. J. Pharmacol. 818, 191\u2013197 (2018).","journal-title":"Eur. J. Pharmacol."},{"key":"732_CR38","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.vaccine.2005.08.055","volume":"24","author":"M Spruth","year":"2006","unstructured":"Spruth, M. et al. A double-inactivated whole virus candidate SARS coronavirus vaccine stimulates neutralising and protective antibody responses. Vaccine 24, 652\u2013661 (2006).","journal-title":"Vaccine"},{"key":"732_CR39","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug Discov."},{"key":"732_CR40","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature02463","volume":"428","author":"ZY Yang","year":"2004","unstructured":"Yang, Z. Y. et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561\u2013564 (2004).","journal-title":"Nature"},{"key":"732_CR41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1471-2172-11-65","volume":"11","author":"BS Shim","year":"2010","unstructured":"Shim, B. S. et al. Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus\/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses. BMC Immunol. 11, 65 (2010).","journal-title":"BMC Immunol."},{"key":"732_CR42","doi-asserted-by":"crossref","first-page":"4736","DOI":"10.1016\/S0264-410X(03)00525-5","volume":"21","author":"J Pitcovski","year":"2003","unstructured":"Pitcovski, J. et al. Development and large-scale use of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickens. Vaccine 21, 4736\u20134743 (2003).","journal-title":"Vaccine"},{"key":"732_CR43","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1038\/s41565-019-0512-0","volume":"14","author":"J Conniot","year":"2019","unstructured":"Conniot, J. et al. Immunization with mannosylated nanovaccines and inhibition of the immune-suppressing microenvironment sensitizes melanoma to immune checkpoint modulators. Nat. Nanotechnol. 14, 891\u2013901 (2019).","journal-title":"Nat. Nanotechnol."},{"key":"732_CR44","doi-asserted-by":"crossref","first-page":"e00298","DOI":"10.1128\/CVI.00298-16","volume":"24","author":"KB Lauer","year":"2017","unstructured":"Lauer, K. B., Borrow, R. & Blanchard, T. J. Multivalent and multipathogen viral vector vaccines. Clin. Vaccine Immunol. 24, e00298\u201316 (2017).","journal-title":"Clin. Vaccine Immunol."},{"key":"732_CR45","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","volume":"8","author":"SJ Draper","year":"2010","unstructured":"Draper, S. J. & Heeney, J. L. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 8, 62\u201373 (2010).","journal-title":"Nat. Rev. Microbiol."},{"key":"732_CR46","doi-asserted-by":"crossref","first-page":"e35421","DOI":"10.1371\/journal.pone.0035421","volume":"7","author":"CT Tseng","year":"2012","unstructured":"Tseng, C. T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One 7, e35421 (2012).","journal-title":"PLoS One"},{"key":"732_CR47","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","volume":"3","author":"A Savarino","year":"2003","unstructured":"Savarino, A., Boelaert, J. R., Cassone, A., Majori, G. & Cauda, R. Effects of chloroquine on viral infections: an old drug against today\u2019s diseases? Lancet Infect. Dis. 3, 722\u2013727 (2003).","journal-title":"Lancet Infect. Dis."},{"key":"732_CR48","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","volume":"2","author":"MJ Vincent","year":"2005","unstructured":"Vincent, M. J. et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol. J. 2, 69 (2005).","journal-title":"Virol. J."},{"key":"732_CR49","doi-asserted-by":"crossref","first-page":"898","DOI":"10.3390\/cells8080898","volume":"8","author":"A Alunno","year":"2019","unstructured":"Alunno, A., Padjen, I., Fanouriakis, A. & Boumpas, D. T. Pathogenic and therapeutic relevance of JAK\/STAT signaling in Systemic Lupus Erythematosus: Integration of distinct inflammatory pathways and the prospect of their inhibition with an oral agent. Cells 8, 898 (2019).","journal-title":"Cells"},{"key":"732_CR50","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41565-020-0674-9","volume":"15","author":"T Hu","year":"2020","unstructured":"Hu, T., Frieman, M. & Wolfram, J. Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat. Nanotechnol. 15, 247\u2013249 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"732_CR51","doi-asserted-by":"publisher","unstructured":"Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature https:\/\/doi.org\/10.1038\/s41586-020-2312-y (2020).","DOI":"10.1038\/s41586-020-2312-y"},{"key":"732_CR52","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","volume":"55","author":"CA Devaux","year":"2020","unstructured":"Devaux, C. A., Rolain, J. M., Colson, P. & Raoult, D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int. J. Antimicrob. Agents 55, 105938 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"732_CR53","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","volume":"50","author":"JD Molina","year":"2020","unstructured":"Molina, J. D. et al. No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection. M\u00e9decine et Maladies Infectieuses 50, 384 (2020).","journal-title":"M\u00e9decine et Maladies Infectieuses"},{"key":"732_CR54","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2174\/092986708784049658","volume":"15","author":"YS Boriskin","year":"2008","unstructured":"Boriskin, Y. S., Leneva, I. A., Pecheur, E. I. & Polyak, S. J. Arbidol: a broad-spectrum antiviral compound that blocks viral fusion. Curr. Med. Chem. 15, 997\u20131005 (2008).","journal-title":"Curr. Med. Chem."},{"key":"732_CR55","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/aps.2013.54","volume":"34","author":"Q Liu","year":"2013","unstructured":"Liu, Q. et al. Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection. Acta Pharmacol. Sin. 34, 1075\u20131083 (2013).","journal-title":"Acta Pharmacol. Sin."},{"key":"732_CR56","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1007\/s00705-007-0974-5","volume":"152","author":"L Shi","year":"2007","unstructured":"Shi, L. et al. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhinovirus, coxsackie virus and adenovirus in vitro and in vivo. Arch. Virol. 152, 1447\u20131455 (2007).","journal-title":"Arch. Virol."},{"key":"732_CR57","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1073\/pnas.1617020114","volume":"114","author":"RU Kadam","year":"2017","unstructured":"Kadam, R. U. & Wilson, I. A. Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol. Proc. Natl Acad. Sci. USA 114, 206\u2013214 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"732_CR58","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-13940-6","volume":"11","author":"TP Sheahan","year":"2020","unstructured":"Sheahan, T. P. et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat. Commun. 11, 222 (2020).","journal-title":"Nat. Commun."},{"key":"732_CR59","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/d41587-020-00003-1","volume":"38","author":"C Harrison","year":"2020","unstructured":"Harrison, C. Coronavirus puts drug repurposing on the fast track. Nat. Biotechnol. 38, 379\u2013381 (2020).","journal-title":"Nat. Biotechnol."},{"key":"732_CR60","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","volume":"347","author":"MW Fried","year":"2002","unstructured":"Fried, M. W. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347, 975\u2013982 (2002).","journal-title":"N. Engl. J. Med."},{"key":"732_CR61","first-page":"218","volume":"3","author":"HS Te","year":"2007","unstructured":"Te, H. S., Randall, G. & Jensen, D. M. Mechanism of action of ribavirin in the treatment of chronic hepatitis C. Gastroenterol. Hepatol. (N Y) 3, 218\u2013225 (2007).","journal-title":"Gastroenterol. Hepatol. (N Y)"},{"key":"732_CR62","doi-asserted-by":"crossref","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","volume":"9","author":"ML Agostini","year":"2018","unstructured":"Agostini, M. L. et al. Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease. mBio 9, e00221\u201300218 (2018).","journal-title":"mBio"},{"key":"732_CR63","first-page":"NEJMoa2007764","volume":"22","author":"J Beigel","year":"2020","unstructured":"Beigel, J. et al. Remdesivir for the treatment of Covid-19 \u2014 preliminary report. N. Engl. J. Med. 22, NEJMoa2007764 (2020).","journal-title":"N. Engl. J. Med."},{"key":"732_CR64","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/d41586-020-00444-3","volume":"578","author":"A Maxmen","year":"2020","unstructured":"Maxmen, A. More than 80 clinical trials launch to test coronavirus treatments. Nature 578, 347\u2013348 (2020).","journal-title":"Nature"},{"key":"732_CR65","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41586-019-1906-8","volume":"577","author":"F Petitprez","year":"2020","unstructured":"Petitprez, F. et al. B cells are associated with survival and immunotherapy response in sarcoma. Nature 577, 556\u2013560 (2020).","journal-title":"Nature"},{"key":"732_CR66","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","volume":"323","author":"D Wang","year":"2020","unstructured":"Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061\u20131069 (2020).","journal-title":"JAMA"},{"key":"732_CR67","doi-asserted-by":"crossref","first-page":"e105617","DOI":"10.1371\/journal.pone.0105617","volume":"9","author":"RR Wang","year":"2014","unstructured":"Wang, R. R. et al. Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. PLoS One 9, e105617 (2014).","journal-title":"PLoS One"},{"key":"732_CR68","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","volume":"395","author":"P Richardson","year":"2020","unstructured":"Richardson, P. et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 395, e30\u2013e31 (2020).","journal-title":"Lancet"},{"key":"732_CR69","unstructured":"Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19. RECOVERY https:\/\/www.recoverytrial.net\/news\/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19 (2020)."},{"key":"732_CR70","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1056\/NEJMoa2008975","volume":"383","author":"HR Reynolds","year":"2020","unstructured":"Reynolds, H. R. et al. Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19. N. Engl. J. Med. 383, 2441\u20132448 (2020).","journal-title":"N. Engl. J. Med."},{"key":"732_CR71","doi-asserted-by":"crossref","first-page":"72","DOI":"10.12688\/f1000research.22211.2","volume":"9","author":"RL Kruse","year":"2020","unstructured":"Kruse, R. L. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Res 9, 72 (2020).","journal-title":"F1000Res"},{"key":"732_CR72","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1080\/01652176.2020.1727993","volume":"40","author":"YS Malik","year":"2020","unstructured":"Malik, Y. S. et al. Emerging novel coronavirus (2019-nCoV)-current scenario, evolutionary perspective based on genome analysis and recent developments. Vet Q 40, 68\u201376 (2020).","journal-title":"Vet Q"},{"key":"732_CR73","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280 (2020).","journal-title":"Cell"},{"key":"732_CR74","first-page":"1","volume":"3","author":"W-H Chen","year":"2020","unstructured":"Chen, W.-H., Strych, U., Hotez, P. J. & Bottazzi, M. E. The SARS-CoV-2 vaccine pipeline: An overview. Current Tropical Medicine Reports 3, 1\u20134 (2020).","journal-title":"Current Tropical Medicine Reports"},{"key":"732_CR75","doi-asserted-by":"crossref","unstructured":"Hikmet, F., M\u00e9ar, L, Uhl\u00e9n, M & Lindskog, C. The protein expression profile of ACE2 in human tissues. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2020.03.31.016048v1 (2020).","DOI":"10.1101\/2020.03.31.016048"},{"key":"732_CR76","first-page":"55","volume":"92","author":"YC Li","year":"2020","unstructured":"Li, Y. C., Bai, W. Z. & Hashikawa, T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J. Med. Virol. 92, 55\u2013555 (2020).","journal-title":"J. Med. Virol."},{"key":"732_CR77","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1111\/j.1471-4159.2008.05723.x","volume":"107","author":"H Xia","year":"2008","unstructured":"Xia, H. & Lazartigues, E. Angiotensin-converting enzyme 2 in the brain: properties and future directions. J. Neurochem. 107, 1482\u20131494 (2008).","journal-title":"J. Neurochem."},{"key":"732_CR78","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S1359-6446(04)03320-3","volume":"10","author":"Y Kliger","year":"2005","unstructured":"Kliger, Y., Levanon, E. Y. & Gerber, D. From genome to antivirals: SARS as a test tube. Drug Discov. Today 10, 345\u2013352 (2005).","journal-title":"Drug Discov. Today"},{"key":"732_CR79","doi-asserted-by":"crossref","first-page":"15748","DOI":"10.1073\/pnas.0403812101","volume":"101","author":"SA Jeffers","year":"2004","unstructured":"Jeffers, S. A. et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proc. Natl Acad. Sci. USA 101, 15748\u201315753 (2004).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"732_CR80","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cell.2020.02.058","volume":"181","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281\u2013292 (2020).","journal-title":"Cell"},{"key":"732_CR81","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","volume":"17","author":"W Tai","year":"2020","unstructured":"Tai, W. et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell. Mol. Immunol. 17, 613\u2013620 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"732_CR82","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol 5, 562\u2013569 (2020).","journal-title":"Nat. Microbiol"},{"key":"732_CR83","volume":"8","author":"Y Yuan","year":"2017","unstructured":"Yuan, Y. et al. Cryo-EM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun. 8, 15092 (2017).","journal-title":"Nat. Commun."},{"key":"732_CR84","doi-asserted-by":"crossref","first-page":"e7870","DOI":"10.1371\/journal.pone.0007870","volume":"4","author":"YW Kam","year":"2009","unstructured":"Kam, Y. W. et al. Cleavage of the SARS coronavirus spike glycoprotein by airway proteases enhances virus entry into human bronchial epithelial cells in vitro. PLoS One 4, e7870 (2009).","journal-title":"PLoS One"},{"key":"732_CR85","doi-asserted-by":"crossref","first-page":"12543","DOI":"10.1073\/pnas.0503203102","volume":"102","author":"S Matsuyama","year":"2005","unstructured":"Matsuyama, S., Ujike, M., Morikawa, S., Tashiro, M. & Taguchi, F. Protease-mediated enhancement of severe acute respiratory syndrome coronavirus infection. Proc. Natl Acad. Sci. USA 102, 12543\u201312547 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"732_CR86","doi-asserted-by":"crossref","first-page":"271\u2013280","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271\u2013280\u2013e278 (2020).","journal-title":"Cell"},{"key":"732_CR87","doi-asserted-by":"crossref","first-page":"11876","DOI":"10.1073\/pnas.0505577102","volume":"102","author":"G Simmons","year":"2005","unstructured":"Simmons, G. et al. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc. Natl Acad. Sci. USA 102, 11876\u201311881 (2005).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"732_CR88","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1126\/science.1069132","volume":"296","author":"P Ahlquist","year":"2002","unstructured":"Ahlquist, P. & RNA-dependent, R. N. A. polymerases, viruses, and RNA silencing. Science 296, 1270\u20131273 (2002).","journal-title":"Science"},{"key":"732_CR89","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","volume":"10","author":"X Li","year":"2020","unstructured":"Li, X., Geng, M., Peng, Y., Meng, L. & Lu, S. Molecular immune pathogenesis and diagnosis of COVID-19. J. Pharm. Anal. 10, 102\u2013108 (2020).","journal-title":"J. Pharm. Anal."},{"key":"732_CR90","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","volume":"92","author":"G Li","year":"2020","unstructured":"Li, G. et al. Coronavirus infections and immune responses. J. Med. Virol. 92, 424\u2013432 (2020).","journal-title":"J. Med. Virol."},{"key":"732_CR91","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E de Wit","year":"2016","unstructured":"de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523\u2013534 (2016).","journal-title":"Nat. Rev. Microbiol."},{"key":"732_CR92","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/bs.aivir.2016.08.006","volume":"96","author":"E Kindler","year":"2016","unstructured":"Kindler, E., Thiel, V. & Weber, F. Interaction of SARS and MERS coronaviruses with the antiviral interferon response. Adv. Virus Res. 96, 219\u2013243 (2016).","journal-title":"Adv. Virus Res."},{"key":"732_CR93","doi-asserted-by":"crossref","first-page":"E1012","DOI":"10.1073\/pnas.1706928115","volume":"115","author":"VD Menachery","year":"2018","unstructured":"Menachery, V. D. et al. MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape. Proc. Natl Acad. Sci. USA 115, E1012\u2013E1021 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"732_CR94","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","volume":"17","author":"HY Zheng","year":"2020","unstructured":"Zheng, H. Y. et al. Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients. Cell. Mol. Immunol. 17, 541\u2013543 (2020).","journal-title":"Cell. Mol. Immunol."},{"key":"732_CR95","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/imr.12098","volume":"255","author":"BS Graham","year":"2013","unstructured":"Graham, B. S. Advances in antiviral vaccine development. Immunol. Rev. 255, 230\u2013242 (2013).","journal-title":"Immunol. Rev."},{"key":"732_CR96","unstructured":"Bao, L. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. Preprint at https:\/\/www.biorxiv.org\/content\/10.1101\/2020.03.13.990226v1 (2020)."},{"key":"732_CR97","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41591-020-0819-2","volume":"26","author":"I Thevarajan","year":"2020","unstructured":"Thevarajan, I. et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat. Med. 26, 453\u2013455 (2020).","journal-title":"Nat. Med."},{"key":"732_CR98","unstructured":"Zhao, J.et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. ciaa344 (2020)."},{"key":"732_CR99","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","volume":"323","author":"C Shen","year":"2020","unstructured":"Shen, C. Treatment of 5 critically ill Patients with COVID-19 with convalescent plasma. JAMA 323, 1582\u20131589 (2020).","journal-title":"JAMA"},{"key":"732_CR100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2020.05.008","volume":"182","author":"AW Grifoni","year":"2020","unstructured":"Grifoni, A. W. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 182, 1\u20139 (2020).","journal-title":"Cell"},{"key":"732_CR101","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","volume":"5","author":"M Letko","year":"2020","unstructured":"Letko, M., Marzi, A. & Munster, V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562\u2013569 (2020).","journal-title":"Nat. Microbiol."},{"key":"732_CR102","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","volume":"19","author":"SG Reed","year":"2013","unstructured":"Reed, S. G., Orr, M. T. & Fox, C. B. Key roles of adjuvants in modern vaccines. Nat. Med. 19, 1597\u20131608 (2013).","journal-title":"Nat. Med."},{"key":"732_CR103","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12250-018-0009-2","volume":"33","author":"F Luo","year":"2018","unstructured":"Luo, F. et al. Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine. Virol. Sin. 33, 201\u2013204 (2018).","journal-title":"Virol. Sin."},{"key":"732_CR104","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1080\/22221751.2019.1620083","volume":"8","author":"W Jia","year":"2019","unstructured":"Jia, W. et al. Single intranasal immunization with chimpanzee adenovirus-based vaccine induces sustained and protective immunity against MERS-CoV infection. Emerg. Microbes Infect. 8, 760\u2013772 (2019).","journal-title":"Emerg. Microbes Infect."},{"key":"732_CR105","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines \u2014 a new era in vaccinology. Nat. Rev. Drug. Discov. 17, 261\u2013279 (2018).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"732_CR106","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1166\/jbn.2014.1715","volume":"10","author":"G Tiram","year":"2014","unstructured":"Tiram, G., Scomparin, A., Ofek, P. & Satchi-Fainaro, R. Interfering cancer with polymeric siRNA nanomedicines. J. Biomed. Nanotechnol. 10, 50\u201366 (2014).","journal-title":"J. Biomed. Nanotechnol."},{"key":"732_CR107","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0169-409X(02)00228-4","volume":"55","author":"J Panyam","year":"2003","unstructured":"Panyam, J. & Labhasetwar, V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv. Drug Deliv. Rev. 55, 329\u2013347 (2003).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"732_CR108","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/nrd4477","volume":"14","author":"O Veiseh","year":"2015","unstructured":"Veiseh, O., Tang, B. C., Whitehead, K. A., Anderson, D. G. & Langer, R. Managing diabetes with nanomedicine: challenges and opportunities. Nat. Rev. Drug Discov. 14, 45\u201357 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"732_CR109","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1166\/jbn.2016.2157","volume":"12","author":"J Mograo","year":"2016","unstructured":"Mograo, J., da Costa, C. A., Gaspar, R. & Florindo, H. F. Modulation of dendritic cells by nanotechnology-based immunotherapeutic strategies. J. Biomed. Nanotechnol. 12, 405\u2013434 (2016).","journal-title":"J. Biomed. Nanotechnol."},{"key":"732_CR110","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.bbrc.2015.08.023","volume":"468","author":"V Sainz","year":"2015","unstructured":"Sainz, V. et al. Regulatory aspects on nanomedicines. Biochem. Biophys. Res. Commun. 468, 504\u2013510 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"732_CR111","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1039\/C7MD00158D","volume":"9","author":"Y Shen","year":"2018","unstructured":"Shen, Y., Hao, T., Ou, S., Hu, C. & Chen, L. Applications and perspectives of nanomaterials in novel vaccine development. Medchemcomm 9, 226\u2013238 (2018).","journal-title":"Medchemcomm"},{"key":"732_CR112","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fcimb.2013.00013","volume":"3","author":"AE Gregory","year":"2013","unstructured":"Gregory, A. E., Titball, R. & Williamson, D. Vaccine delivery using nanoparticles. Front. Cell. Infect. Microbiol. 3, 13 (2013).","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"732_CR113","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11705-018-1729-4","volume":"13","author":"F Qi","year":"2019","unstructured":"Qi, F., Wu, J., Li, H. & Ma, G. Recent research and development of PLGA\/PLA microspheres\/nanoparticles: A review in scientific and industrial aspects. Front. Chem. Sci. Eng. 13, 14\u201327 (2019).","journal-title":"Front. Chem. Sci. Eng."},{"key":"732_CR114","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.drudis.2015.11.015","volume":"21","author":"CK Chang","year":"2016","unstructured":"Chang, C. K., Lo, S. C., Wang, Y. S. & Hou, M. H. Recent insights into the development of therapeutics against coronavirus diseases by targeting N protein. Drug Discov. Today 21, 562\u2013572 (2016).","journal-title":"Drug Discov. Today"},{"key":"732_CR115","doi-asserted-by":"crossref","DOI":"10.1038\/srep46426","volume":"7","author":"N Van Hoeven","year":"2017","unstructured":"Van Hoeven, N. et al. A formulated TLR7\/8 agonist is a flexible, highly potent and effective adjuvant for pandemic influenza vaccines. Sci Rep 7, 46426 (2017).","journal-title":"Sci Rep"},{"key":"732_CR116","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1365-2567.2005.02258.x","volume":"117","author":"A Kumar","year":"2006","unstructured":"Kumar, A., Zhang, J. & Yu, F. S. Toll-like receptor 3 agonist poly(I:C)-induced antiviral response in human corneal epithelial cells. Immunology 117, 11\u201321 (2006).","journal-title":"Immunology"},{"key":"732_CR117","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.it.2008.09.006","volume":"30","author":"SG Reed","year":"2009","unstructured":"Reed, S. G., Bertholet, S., Coler, R. N. & Friede, M. New horizons in adjuvants for vaccine development. Trends Immunol. 30, 23\u201332 (2009).","journal-title":"Trends Immunol."},{"key":"732_CR118","doi-asserted-by":"crossref","first-page":"e16333","DOI":"10.1371\/journal.pone.0016333","volume":"6","author":"RN Coler","year":"2011","unstructured":"Coler, R. N. et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 6, e16333 (2011).","journal-title":"PLoS One"},{"key":"732_CR119","doi-asserted-by":"crossref","DOI":"10.1186\/1479-0556-3-7","volume":"3","author":"A Azizi","year":"2005","unstructured":"Azizi, A. et al. A combined nucleocapsid vaccine induces vigorous SARS-CD8+ T-cell immune responses. Genet. Vaccines Ther. 3, 7 (2005).","journal-title":"Genet. Vaccines Ther."},{"key":"732_CR120","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jconrel.2017.05.014","volume":"258","author":"E Zupancic","year":"2017","unstructured":"Zupancic, E. et al. Rational design of nanoparticles towards targeting antigen-presenting cells and improved T cell priming. J. Control. Release 258, 182\u2013195 (2017).","journal-title":"J. Control. Release"},{"key":"732_CR121","doi-asserted-by":"crossref","first-page":"e1701854","DOI":"10.1126\/sciadv.1701854","volume":"4","author":"MM Linehan","year":"2018","unstructured":"Linehan, M. M. et al. A minimal RNA ligand for potent RIG-I activation in living mice. Sci. Adv. 4, e1701854 (2018).","journal-title":"Sci. Adv."},{"key":"732_CR122","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"732_CR123","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang, C., Maruggi, G., Shan, H. & Li, J. Advances in mRNA vaccines for infectious diseases. Front. Immunol. 10, 594 (2019).","journal-title":"Front. Immunol."},{"key":"732_CR124","doi-asserted-by":"crossref","unstructured":"Iavarone, C., O\u2019Hagan D, T., Yu, D., Delahaye, N. F. & Ulmer, J. B. Mechanism of action of mRNA-based vaccines. Expert. Rev. Vaccines 16, 871\u2013881 (2017).","DOI":"10.1080\/14760584.2017.1355245"},{"key":"732_CR125","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1016\/S0140-6736(17)31665-3","volume":"390","author":"M Alberer","year":"2017","unstructured":"Alberer, M. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390, 1511\u20131520 (2017).","journal-title":"Lancet"},{"key":"732_CR126","doi-asserted-by":"publisher","unstructured":"Corbett K. S. et al. SARS-CoV-2 mRNA vaccine development enabled by prototype pathogen 1 preparedness. bioRxiv https:\/\/doi.org\/10.1101\/2020.06.11.145920 (2020)","DOI":"10.1101\/2020.06.11.145920"},{"key":"732_CR127","unstructured":"Moderna ships mRNA vaccine against novel coronavirus (mRNA-1273) for phase 1 study. Moderna https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-ships-mrna-vaccine-against-novel-coronavirus-mrna-1273 (2020)."},{"key":"732_CR128","doi-asserted-by":"crossref","first-page":"e123158","DOI":"10.1172\/jci.insight.123158","volume":"4","author":"L Liu","year":"2019","unstructured":"Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4, e123158 (2019).","journal-title":"JCI Insight"},{"key":"732_CR129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/jmv.20499","volume":"78","author":"L Zhang","year":"2006","unstructured":"Zhang, L. et al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. J. Med. Virol. 78, 1\u20138 (2006).","journal-title":"J. Med. Virol."},{"key":"732_CR130","doi-asserted-by":"crossref","first-page":"4234","DOI":"10.1128\/JVI.06791-11","volume":"86","author":"C Clay","year":"2012","unstructured":"Clay, C. et al. Primary severe acute respiratory syndrome coronavirus infection limits replication but not lung inflammation upon homologous rechallenge. J. Virol. 86, 4234\u20134244 (2012).","journal-title":"J. Virol."},{"key":"732_CR131","doi-asserted-by":"crossref","first-page":"9318","DOI":"10.1128\/JVI.01049-10","volume":"84","author":"J Zhao","year":"2010","unstructured":"Zhao, J., Zhao, J. & Perlman, S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J. Virol. 84, 9318\u20139325 (2010).","journal-title":"J. Virol."},{"key":"732_CR132","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.immuni.2016.05.006","volume":"44","author":"J Zhao","year":"2016","unstructured":"Zhao, J. et al. Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity 44, 1379\u20131391 (2016).","journal-title":"Immunity"},{"key":"732_CR133","doi-asserted-by":"crossref","unstructured":"Wu, F. et al. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications. Preprint at https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.30.20047365v2 (2020).","DOI":"10.2139\/ssrn.3566211"},{"key":"732_CR134","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/j.vaccine.2008.01.025","volume":"26","author":"L Du","year":"2008","unstructured":"Du, L. et al. Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine 26, 1644\u20131651 (2008).","journal-title":"Vaccine"},{"key":"732_CR135","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1128\/JVI.00087-13","volume":"87","author":"C Fett","year":"2013","unstructured":"Fett, C., DeDiego, M. L., Regla-Nava, J. A., Enjuanes, L. & Perlman, S. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein. J. Virol. 87, 6551\u20136559 (2013).","journal-title":"J. Virol."},{"key":"732_CR136","first-page":"450","volume":"57","author":"XH Yang","year":"2007","unstructured":"Yang, X. H. et al. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection. Comp Med 57, 450\u2013459 (2007).","journal-title":"Comp Med"},{"key":"732_CR137","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba, K. et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat. Med. 11, 875\u2013879 (2005).","journal-title":"Nat. Med."},{"key":"732_CR138","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai, Y. et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature 436, 112\u2013116 (2005).","journal-title":"Nature"},{"key":"732_CR139","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1038\/nm.2972","volume":"18","author":"RL Graham","year":"2012","unstructured":"Graham, R. L. et al. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat. Med. 18, 1820\u20131826 (2012).","journal-title":"Nat. Med."},{"key":"732_CR140","doi-asserted-by":"crossref","first-page":"e1000849","DOI":"10.1371\/journal.ppat.1000849","volume":"6","author":"MB Frieman","year":"2010","unstructured":"Frieman, M. B. et al. SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog. 6, e1000849 (2010).","journal-title":"PLoS Pathog."},{"key":"732_CR141","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.virusres.2007.03.025","volume":"133","author":"A Roberts","year":"2008","unstructured":"Roberts, A. et al. Animal models and vaccines for SARS-CoV infection. Virus Res. 133, 20\u201332 (2008).","journal-title":"Virus Res."},{"key":"732_CR142","doi-asserted-by":"crossref","first-page":"13022","DOI":"10.1073\/pnas.1000475107","volume":"107","author":"LD Shultz","year":"2010","unstructured":"Shultz, L. D. et al. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD\/SCID\/IL2r gamma(null) humanized mice. Proc. Natl Acad. Sci. USA 107, 13022\u201313027 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"732_CR143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cell.2020.05.027","volume":"182","author":"RL Jiang","year":"2020","unstructured":"Jiang, R. L. et al. Pathogenesis of SARS-CoV-2 in transgenic mice expressing human angiotensin-converting enzyme 2. Cell 182, 1\u20139 (2020).","journal-title":"Cell"},{"key":"732_CR144","doi-asserted-by":"crossref","first-page":"7264","DOI":"10.1128\/JVI.00737-08","volume":"82","author":"J Netland","year":"2008","unstructured":"Netland, J., Meyerholz, D. K., Moore, S., Cassell, M. & Perlman, S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J. Virol. 82, 7264\u20137275 (2008).","journal-title":"J. Virol."},{"key":"732_CR145","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JVI.02012-06","volume":"81","author":"PB McCray Jr.","year":"2007","unstructured":"McCray, P. B. Jr. et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 81, 813\u2013821 (2007).","journal-title":"J. Virol."},{"key":"732_CR146","doi-asserted-by":"crossref","first-page":"S308","DOI":"10.1093\/infdis\/jiw248","volume":"214","author":"JR Spengler","year":"2016","unstructured":"Spengler, J. R. et al. Ebola virus replication and disease without immunopathology in mice expressing transgenes to support human myeloid and lymphoid cell engraftment. J. Infect. Dis. 214, S308\u2013S318 (2016).","journal-title":"J. Infect. Dis."},{"key":"732_CR147","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1038\/nri3311","volume":"12","author":"LD Shultz","year":"2012","unstructured":"Shultz, L. D., Brehm, M. A., Garcia-Martinez, J. V. & Greiner, D. L. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 12, 786\u2013798 (2012).","journal-title":"Nat. Rev. Immunol."},{"key":"732_CR148","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jim.2014.02.011","volume":"410","author":"MA Brehm","year":"2014","unstructured":"Brehm, M. A., Wiles, M. V., Greiner, D. L. & Shultz, L. D. Generation of improved humanized mouse models for human infectious diseases. J. Immunol. Methods 410, 3\u201317 (2014).","journal-title":"J. Immunol. Methods"},{"key":"732_CR149","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/imr.12109","volume":"255","author":"TJ Braciale","year":"2013","unstructured":"Braciale, T. J. & Hahn, Y. S. Immunity to viruses. Immunol. Rev. 255, 5\u201312 (2013).","journal-title":"Immunol. Rev."},{"key":"732_CR150","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/095632020601700505","volume":"17","author":"DL Barnard","year":"2006","unstructured":"Barnard, D. L. et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB\/c mice. Antivir. Chem. Chemother. 17, 275\u2013284 (2006).","journal-title":"Antivir. Chem. Chemother."},{"key":"732_CR151","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1164\/rccm.201706-1172OC","volume":"197","author":"YM Arabi","year":"2018","unstructured":"Arabi, Y. M. et al. Corticosteroid therapy for critically ill patients with Middle East Respiratory Syndrome. Am. J. Respir. Crit. Care Med 197, 757\u2013767 (2018).","journal-title":"J. Respir. Crit. Care Med"},{"key":"732_CR152","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jinf.2004.09.008","volume":"51","author":"TW Auyeung","year":"2005","unstructured":"Auyeung, T. W. et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J. Infect. 51, 98\u2013102 (2005).","journal-title":"J. Infect."},{"key":"732_CR153","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","volume":"395","author":"CD Russell","year":"2020","unstructured":"Russell, C. D., Millar, J. E. & Baillie, J. K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet 395, 473\u2013475 (2020).","journal-title":"Lancet"},{"key":"732_CR154","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","volume":"19","author":"G Li","year":"2020","unstructured":"Li, G. & De Clercq, E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat. Rev. Drug Discov. 19, 149\u2013150 (2020).","journal-title":"Nat. Rev. Drug Discov."},{"key":"732_CR155","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054\u20131062 (2020).","journal-title":"Lancet"},{"key":"732_CR156","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/nm0509-496","volume":"15","author":"RS Hotchkiss","year":"2009","unstructured":"Hotchkiss, R. S., Coopersmith, C. M., McDunn, J. E. & Ferguson, T. A. The sepsis seesaw: tilting toward immunosuppression. Nat. Med. 15, 496\u2013497 (2009).","journal-title":"Nat. Med."},{"key":"732_CR157","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00281-017-0639-8","volume":"39","author":"BG Chousterman","year":"2017","unstructured":"Chousterman, B. G., Swirski, F. K. & Weber, G. F. Cytokine storm and sepsis disease pathogenesis. Semi.n Immunopathol. 39, 517\u2013528 (2017).","journal-title":"Semi.n Immunopathol."},{"key":"732_CR158","doi-asserted-by":"crossref","DOI":"10.1186\/cc9046","volume":"14","author":"JM Cavaillon","year":"2010","unstructured":"Cavaillon, J. M. & Adib-Conquy, M. Immune status in sepsis: the bug, the site of infection and the severity can make the difference. Crit. Care 14, 167 (2010).","journal-title":"Crit. Care"},{"key":"732_CR159","volume":"15","author":"GP Otto","year":"2011","unstructured":"Otto, G. P. et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit. Care 15, R183 (2011).","journal-title":"Crit. Care"},{"key":"732_CR160","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S1074-7613(04)00051-2","volume":"20","author":"X Zhang","year":"2004","unstructured":"Zhang, X. et al. Structural and functional analysis of the costimulatory receptor programmed death-1. Immunity 20, 337\u2013347 (2004).","journal-title":"Immunity"},{"key":"732_CR161","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.3390\/ijms18112413","volume":"18","author":"NK Patil","year":"2017","unstructured":"Patil, N. K., Guo, Y., Luan, L. & Sherwood, E. R. Targeting immune cell checkpoints during sepsis. Int. J. Mol. Sci. 18, 2413 (2017).","journal-title":"Int. J. Mol. Sci."},{"key":"732_CR162","doi-asserted-by":"crossref","first-page":"eaav7431","DOI":"10.1126\/scitranslmed.aav7431","volume":"12","author":"M Mayoux","year":"2020","unstructured":"Mayoux, M. et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy. Sci. Transl. Med. 12, eaav7431 (2020).","journal-title":"Sci. Transl. Med."},{"key":"732_CR163","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.3389\/fmicb.2018.03158","volume":"9","author":"K Naran","year":"2018","unstructured":"Naran, K., Nundalall, T., Chetty, S. & Barth, S. Principles of immunotherapy: implications for treatment strategies in cancer and infectious diseases. Front. Microbiol. 9, 3158 (2018).","journal-title":"Front. Microbiol."},{"key":"732_CR164","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1074\/jbc.M708033200","volume":"283","author":"X Zhao","year":"2008","unstructured":"Zhao, X., Nicholls, J. M. & Chen, Y. G. Severe acute respiratory syndrome-associated coronavirus nucleocapsid protein interacts with Smad3 and modulates transforming growth factor-beta signaling. J. Biol. Chem. 283, 3272\u20133280 (2008).","journal-title":"J. Biol. Chem."},{"key":"732_CR165","doi-asserted-by":"crossref","first-page":"e0172592","DOI":"10.1371\/journal.pone.0172592","volume":"12","author":"T Stahnke","year":"2017","unstructured":"Stahnke, T. et al. Suppression of TGF-beta pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro. PLoS One 12, e0172592 (2017).","journal-title":"PLoS One"},{"key":"732_CR166","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1158\/1078-0432.CCR-07-1157","volume":"13","author":"SH Wrzesinski","year":"2007","unstructured":"Wrzesinski, S. H., Wan, Y. Y. & Flavell, R. A. Transforming growth factor-beta and the immune response: implications for anticancer therapy. Clin. Cancer Res. 13, 5262\u20135270 (2007).","journal-title":"Clin. Cancer Res."},{"key":"732_CR167","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev.micro.55.1.255","volume":"55","author":"GC Sen","year":"2001","unstructured":"Sen, G. C. Viruses and interferons. Annu. Rev. Microbiol. 55, 255\u2013281 (2001).","journal-title":"Annu. Rev. Microbiol."},{"key":"732_CR168","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000495172","volume":"51","author":"JH Zhou","year":"2018","unstructured":"Zhou, J. H. et al. Type III interferons in viral infection and antiviral immunity. Cell. Physiol. Biochem. 51, 173\u2013185 (2018).","journal-title":"Cell. Physiol. Biochem."},{"key":"732_CR169","doi-asserted-by":"crossref","unstructured":"Honda, K. & Taniguchi, T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6, 644\u2013658 (2006).","DOI":"10.1038\/nri1900"},{"key":"732_CR170","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/ni712","volume":"2","author":"M Schnare","year":"2001","unstructured":"Schnare, M. et al. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2, 947\u2013950 (2001).","journal-title":"Nat. Immunol."},{"key":"732_CR171","doi-asserted-by":"crossref","first-page":"L1293","DOI":"10.1152\/ajplung.00266.2007","volume":"293","author":"MR White","year":"2007","unstructured":"White, M. R., Tecle, T., Crouch, E. C. & Hartshorn, K. L. Impact of neutrophils on antiviral activity of human bronchoalveolar lavage fluid. Am. J. Physiol. Lung Cell. Mol. Physiol. 293, L1293\u20131299 (2007).","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"732_CR172","doi-asserted-by":"crossref","first-page":"11385","DOI":"10.1128\/JVI.01363-09","volume":"83","author":"CL Wohlford-Lenane","year":"2009","unstructured":"Wohlford-Lenane, C. L. et al. Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J. Virol. 83, 11385\u201311390 (2009).","journal-title":"J. Virol."},{"key":"732_CR173","first-page":"1","volume":"18","author":"K Dhama","year":"2020","unstructured":"Dhama, K. et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum. Vaccin. Immunother. 18, 1\u20137 (2020).","journal-title":"Hum. Vaccin. Immunother."},{"key":"732_CR174","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/jmv.25682","volume":"92","author":"W Ji","year":"2020","unstructured":"Ji, W., Wang, W., Zhao, X., Zai, J. & Li, X. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J. Med. Virol. 92, 433\u2013440 (2020).","journal-title":"J. Med. Virol."},{"key":"732_CR175","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1080\/22221751.2019.1597644","volume":"8","author":"I Widjaja","year":"2019","unstructured":"Widjaja, I. et al. Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. Emerg. Microbes Infect. 8, 516\u2013530 (2019).","journal-title":"Emerg. Microbes Infect."},{"key":"732_CR176","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1517\/13543776.2013.823159","volume":"23","author":"V Kumar","year":"2013","unstructured":"Kumar, V., Jung, Y.-S. & Liang, P.-H. Anti-SARS coronavirus agents: a patent review (2008 \u2013 present). Expert Opin. Ther. Pat. 23, 1337\u20131348 (2013).","journal-title":"Expert Opin. Ther. Pat."},{"key":"732_CR177","doi-asserted-by":"crossref","first-page":"69","DOI":"10.5582\/bst.2020.01020","volume":"14","author":"H Lu","year":"2020","unstructured":"Lu, H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). BioSci. Trends 14, 69\u201371 (2020).","journal-title":"BioSci. Trends"},{"key":"732_CR178","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3390\/jcm9030623","volume":"9","author":"J Pang","year":"2020","unstructured":"Pang, J. et al. Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): A systematic review. J. Clin. Med. 9, 623 (2020).","journal-title":"J. Clin. Med."},{"key":"732_CR179","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1056\/NEJMp1802256","volume":"378","author":"HD Marston","year":"2018","unstructured":"Marston, H. D., Paules, C. I. & Fauci, A. S. Monoclonal Antibodies for Emerging Infectious Diseases - Borrowing from History. N. Engl J. Med. 378, 1469\u20131472 (2018).","journal-title":"N. Engl J. Med."},{"key":"732_CR180","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3389\/fimmu.2019.00594","volume":"10","author":"C Zhang","year":"2019","unstructured":"Zhang, C., Maruggi, G., Shan, H. & Li, J. Advances in mRNA Vaccines for Infectious Diseases. Front. Immunol. 10, 594\u2013594 (2019).","journal-title":"Front. Immunol."},{"key":"732_CR181","unstructured":"Moderna announces positive interim phase 1 data for its mRNA vaccine (mRNA-1273) against novel coronavirus. Moderna https:\/\/investors.modernatx.com\/news-releases\/news-release-details\/moderna-announces-positive-interim-phase-1-data-its-mrna-vaccine (2020)."},{"key":"732_CR182","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejphar.2017.10.035","volume":"818","author":"MM Leiva-Juarez","year":"2018","unstructured":"Leiva-Juarez, M. M. et al. Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir. Eur. J. Pharmacol. 818, 191\u2013197 (2018).","journal-title":"Eur. J. Pharmacol."},{"key":"732_CR183","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.addr.2007.11.003","volume":"60","author":"JM Thompson","year":"2008","unstructured":"Thompson, J. M. & Iwasaki, A. Toll-like receptors regulation of viral infection and disease. Adv. Drug Deliv. Rev. 60, 786\u2013794 (2008).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"732_CR184","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.4049\/jimmunol.1290060","volume":"189","author":"AA Tarhini","year":"2012","unstructured":"Tarhini, A. A., Gogas, H. & Kirkwood, J. M. IFN-\u03b1 in the treatment of melanoma. J. Immunol. 189, 3789\u20133793 (2012).","journal-title":"J. Immunol."},{"key":"732_CR185","doi-asserted-by":"crossref","first-page":"20047","DOI":"10.1074\/jbc.R700004200","volume":"282","author":"S Pestka","year":"2007","unstructured":"Pestka, S. The interferons: 50 years after their discovery, there is much more to learn. J. Biol. Chem. 282, 20047\u201320051 (2007).","journal-title":"J. Biol. Chem."},{"key":"732_CR186","doi-asserted-by":"crossref","first-page":"34","DOI":"10.21037\/sci.2019.08.11","volume":"6","author":"P Saeedi","year":"2019","unstructured":"Saeedi, P., Halabian, R. & Imani Fooladi, A. A. A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies. Stem Cell Investig. 6, 34\u201334 (2019).","journal-title":"Stem Cell Investig."},{"key":"732_CR187","unstructured":"WHO Director-General\u2019s opening remarks at the media briefing on COVID-19 - 27 March 2020. World Health Organization https:\/\/www.who.int\/dg\/speeches\/detail\/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19-27-march-2020 (2020)."},{"key":"732_CR188","unstructured":"\u201cSolidarity\u201d clinical trial for COVID-19 treatments. World Health Organization (https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/global-research-on-novel-coronavirus-2019-ncov\/solidarity-clinical-trial-for-covid-19-treatments (2020)."},{"key":"732_CR189","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","volume":"8","author":"KA Whitehead","year":"2009","unstructured":"Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129\u2013138 (2009).","journal-title":"Nat. Rev. Drug Discov."},{"key":"732_CR190","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1021\/acs.biomac.5b01335","volume":"17","author":"A Kim","year":"2016","unstructured":"Kim, A. et al. Intracellular delivery of charge-converted monoclonal antibodies by combinatorial design of block\/homo polyion complex micelles. Biomacromolecules 17, 446\u2013453 (2016).","journal-title":"Biomacromolecules"},{"key":"732_CR191","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cellimm.2014.01.003","volume":"287","author":"M Chen","year":"2014","unstructured":"Chen, M., Ouyang, H., Zhou, S., Li, J. & Ye, Y. PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses. Cell. Immunol. 287, 91\u201399 (2014).","journal-title":"Cell. Immunol."},{"key":"732_CR192","doi-asserted-by":"crossref","first-page":"6906","DOI":"10.1021\/ja102414t","volume":"132","author":"C Lei","year":"2010","unstructured":"Lei, C. et al. Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy. J. Am. Chem. Soc. 132, 6906\u20136907 (2010).","journal-title":"J. Am. Chem. Soc."},{"key":"732_CR193","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/ijc.1578","volume":"97","author":"TL ten Hagen","year":"2002","unstructured":"ten Hagen, T. L., Seynhaeve, A. L., van Tiel, S. T., Ruiter, D. J. & Eggermont, A. M. Pegylated liposomal tumor necrosis factor-alpha results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil) in soft tissue sarcoma-bearing rats. Int. J. Cancer 97, 115\u2013120 (2002).","journal-title":"Int. J. Cancer"},{"key":"732_CR194","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1182\/blood-2006-12-063594","volume":"109","author":"SS Neelapu","year":"2007","unstructured":"Neelapu, S. S. et al. A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. Blood 109, 5160\u20135163 (2007).","journal-title":"Blood"},{"key":"732_CR195","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41565-020-0674-9","volume":"15","author":"TY Hu","year":"2020","unstructured":"Hu, T. Y., Frieman, M. & Wolfram, J. Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat. Nanotechnol. 15, 247\u2013249 (2020).","journal-title":"Nat. Nanotechnol."},{"key":"732_CR196","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1002\/jmv.25839","volume":"92","author":"A Hadadi","year":"2020","unstructured":"Hadadi, A., Mortezazadeh, M., Kolahdouzan, K. & Alavian, G. Does recombinant human Erythropoietin administration in critically ill COVID-19 patients have miraculous therapeutic effects? J. Med. Virol. 92, 915\u2013918 (2020).","journal-title":"J. Med. Virol."},{"key":"732_CR197","first-page":"257","volume":"49","author":"X Zhang","year":"2019","unstructured":"Zhang, X. & Dong, S. Protective effects of erythropoietin towards acute lung injuries in rats with sepsis and its related mechanisms. Ann. Clin. Lab. Sci. 49, 257\u2013264 (2019).","journal-title":"Ann. Clin. Lab. Sci."},{"key":"732_CR198","first-page":"199","volume":"32","author":"GX Zhang","year":"2018","unstructured":"Zhang, G. X. et al. Protective effect of erythropoietin against lipopolysaccharide induced inflammation and mitochondrial damage in liver. J. Biol. Regul. Homeos. Agents 32, 199\u2013206 (2018).","journal-title":"J. Biol. Regul. Homeos. Agents"},{"key":"732_CR199","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1247\/csf.17018","volume":"42","author":"T Ito","year":"2017","unstructured":"Ito, T., Hamazaki, Y., Takaori-Kondo, A. & Minato, N. Bone Marrow Endothelial Cells Induce Immature and Mature B Cell Egress in Response to Erythropoietin. Cell. Struct. Funct. 42, 149\u2013157 (2017).","journal-title":"Cell. Struct. Funct."},{"key":"732_CR200","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1016\/S0140-6736(20)31103-X","volume":"395","author":"L Verdoni","year":"2020","unstructured":"Verdoni, L. et al. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. Lancet 395, 1771\u20131778 (2020).","journal-title":"Lancet"},{"key":"732_CR201","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(20)31129-6","volume":"395","author":"RM Viner","year":"2020","unstructured":"Viner, R. M. & Whittaker, E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. Lancet 395, 1741\u20131743 (2020).","journal-title":"Lancet"},{"key":"732_CR202","doi-asserted-by":"crossref","unstructured":"Couzin-Frankel, J. Doctors race to understand rare inflammatory condition associated with coronavirus in young people. Science https:\/\/www.sciencemag.org\/news\/2020\/05\/doctors-race-understand-rare-inflammatory-condition-associated-coronavirus-young-people (2020).","DOI":"10.1126\/science.abc9365"},{"key":"732_CR203","unstructured":"Guidance on the Management of Clinical Trials during the COVID-19 (Coronavirus) pandemic (European Medicines Agency, 2020); https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-10\/guidanceclinicaltrials_covid19_en.pdf"},{"key":"732_CR204","doi-asserted-by":"crossref","unstructured":"Andre, F. E. et al. Vaccination greatly reduces disease, disability, death and inequity worldwide. World Health Organization https:\/\/www.who.int\/bulletin\/volumes\/86\/2\/07-040089\/en\/ (2008).","DOI":"10.2471\/BLT.07.040089"},{"key":"732_CR205","unstructured":"Communities vulnerable without immunization against infectious diseases. World Health Organization https:\/\/www.who.int\/malaysia\/news\/detail\/23-04-2020-communities-vulnerable-without-immunization-against-infectious-diseases (2020)."}],"container-title":["Nature Nanotechnology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41565-020-0732-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41565-020-0732-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41565-020-0732-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:00:14Z","timestamp":1684620014000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41565-020-0732-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,13]]},"references-count":205,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["732"],"URL":"https:\/\/doi.org\/10.1038\/s41565-020-0732-3","relation":{},"ISSN":["1748-3387","1748-3395"],"issn-type":[{"value":"1748-3387","type":"print"},{"value":"1748-3395","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,13]]},"assertion":[{"value":"11 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.S.-F. is a Director at the Board of Teva Pharmaceutical Industries Ltd.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}